The unmatched precision of the CyberKnife® System delivers a revolutionary treatment option for men diagnosed with prostate cancer.

- **No incisions — no pain:** Non-surgical treatment eliminates the pain that typically comes with more invasive treatment options.
- **Outpatient procedure:** No general anesthesia or hospitalization.
- **Much faster treatment:** Extraordinary precision maximizes dose delivery so that treatment is completed in just four to five treatments, compared to 35 or more required with traditional radiation treatments.
- **Target the cancer — spare healthy tissue:** Sub-millimeter accuracy and real-time image guidance targets the cancer, sparing health tissue.
- **Minimize side effects — maximize quality of life:** Extreme precision minimizes side effects.

A 21-center study showed that 97 percent of low- and intermediate-risk prostate cancer patients had excellent cancer control five years after receiving stereotactic body radiation therapy (SBRT) administered with the CyberKnife System.

### KEY FINDINGS

**EXCELLENT CANCER CONTROL**
97% of patients experienced excellent cancer control.

**EXTREMELY HIGH SURVIVAL RATE**
Five-year rates almost identical for low- and intermediate-risk patients.

**LOW SIDE EFFECTS**
Toxicity and side effects were uncommon and similar to other radiation therapy treatments including IMRT.

“For men with newly diagnosed prostate cancer, this study changes the game. SBRT provided better cancer control with few side effects, and required only 5 short treatments, without the need for surgery. The CyberKnife System’s realtime image guidance, non-coplanar beam delivery, and sub-millimeter accuracy enabled clinicians across multiple centers to achieve consistent, excellent dose control, with reduced toxicities compared to other radiotherapies.”

Robert M. Meier, M.D., Radiation Oncology Medical Director of the Swedish Radiosurgery Center in Seattle, Washington

**EXCEPTIONAL PATIENT SATISFACTION**

99% of patients would choose CyberKnife treatment again

93% of patients report CyberKnife treatment did not interrupt their normal life routine

98% of patients would recommend CyberKnife treatment to others

**FOR PROSTATE CANCER TREATMENT**

**SUB-MILLIMETER PRECISION WITH AUTOMATIC REAL-TIME MOTION MANAGEMENT**

---

**PRECISION MATTERS**

Effective treatments must deliver maximum dosages and protect healthy tissues. The CyberKnife System’s accuracy is sub-millimeter — its pinpoint precision is within the thickness of a dime — enhancing clinicians’ ability to treat effectively while preserving healthy tissue.

**MOTION MANAGEMENT MATTERS**

The prostate gland can move unpredictably because of normal patient bodily functions. Unlike any other radiation treatment, the CyberKnife System continually tracks and automatically corrects the beam for movement of the prostate in real-time throughout the entire treatment session.

---

**CONFIDENCE IN MOTION**

**COMPUTER GUIDED ROBOTIC DELIVERY**

**INTRACTION IMAGING**

**DYNAMIC MOVEMENT TRACKING AND TREATMENT DELIVERY**

---

**PRECISELY MAXIMIZE DOSE**

**MINIMIZE SIDE EFFECTS**

**MAXIMIZE PATIENT COMFORT**

---

**Important Safety Information:**

Most side effects of radiotherapy, including radiotherapy delivered with Accuray systems, are mild and temporary, often involving fatigue, nausea, and skin irritation. Side effects can be severe, however, leading to pain, alterations in normal body functions (for example, urinary or salivary function), deterioration of quality of life, permanent injury and even death. Side effects can occur during or shortly after radiation treatment or in the months and years following radiation. The nature and severity of side effects depend on many factors, including the size and location of the treated tumor, the treatment technique (for example, the radiation dose), the patient’s general medical condition, to name a few. For more details about the side effects of your radiation therapy, and if treatment with an Accuray product is right for you, ask your doctor.

© 2016 Accuray, the stylized logo, CyberKnife, VSI, AX, TomoTherapy, Tomo, TomoTrol, TomoHOA, Hi-Art, Iris, IrisXchange, RoboGusch, InCue, MultiPlan, Xsight, Synchrony, InTempo, tvView, PlanTouch, QuickPlan, TomoHelical, TomoDirect, TomoDGE, Cleave, VisIO, Planned Adaptive, TQA, TomoLink, TomoPortal, OBI, Connect and AERO are trademarks or registered trademarks of Accuray Incorporated, in the United States and other countries and may not be used or distributed without written authorization from Accuray Incorporated. Use of Accuray Incorporated’s trademarks requires written authorization from Accuray Incorporated. MKT-CX-OY16-0255(1)